Key result
Intravenous glibenclamide reduced lesional net water uptake (β=-2.80; 95% CI -5.07 to -0.53; P=0.016) and midline shift after large hemispheric infarction.
Why the study?
To test the hypothesis that intravenous glibenclamide reduces ischemic brain water uptake in patients with stroke lesions.
Does intravenous glibenclamide reduce lesional net water uptake and midline shift in patients with large hemispheric infarction?
RCT
Does intravenous glibenclamide reduce lesional net water uptake and midline shift in patients with large hemispheric infarction?
Mean Difference: -2.8 (95% CI -5.07–-0.53)
p-value: p=0.016
Intravenous glibenclamide reduces ischemic brain edema accumulation and mass effect after large hemispheric infarction, demonstrating NWU as a modifiable biomarker.
No takes yet. Share an insight, caveat, or question.
Was associated with reduced edema after large hemispheric infarction; leaves open randomized confirmation and clinical outcome effects.
Vorasayan et al. (2019) conducted an RCT in Large hemispheric infarction. Intravenous glibenclamide was evaluated on Lesional net water uptake (NWU) (β=-2.80, 95% CI -5.07 to -0.53, p=0.016). Intravenous glibenclamide reduced lesional net water uptake (β=-2.80; 95% CI -5.07 to -0.53; P=0.016) and midline shift after large hemispheric infarction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: